IBRX - Immunitybio Inc

IBRX - Immunitybio Inc

https://immunitybio.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

What's Going On With ImmunityBio Shares Tuesday? - ImmunityBio ( NASDAQ:IBRX )

Benzinga • 2 weeks, 5 days ago • score: -0.04

ImmunityBio reports all five patients with recurrent glioblastoma show disease control, including two with near complete responses. The company says it is advancing to a Phase 2 trial after what it calls highly encouraging early results. See the 6X seasonal strategy set to target this fall's ...

IBRX Sales Soar 2,540%

Motley Fool • 1 month, 1 week ago • score: -0.12

ImmunityBio ( NASDAQ:IBRX ) , a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue ( GAAP ) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ...

ImmunityBio ( IBRX ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.10

ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio ( IBRX ) Moves to Buy: Rationale Behind the Upgrade

Zacks Commentary • 3 months, 4 weeks ago • score: 0.33

ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ImmunityBio ( IBRX ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months ago • score: -0.01

ImmunityBio (IBRX) delivered earnings and revenue surprises of -25% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.

52W High

$7.48

52W Low

$1.83

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.07

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-8.99

EV/Revenue (<3 favorable)

46.82

P/S (TTM) (<3 favorable)

40.08

P/B (<3 favorable)

N/A

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

69.20%

Institutions (25–75% balanced)

13.25%

Shares Outstanding

945,255,000

Float

193,560,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-06-30 (Overview)

Revenue (TTM)

56,600,000

Gross Profit (TTM)

56,406,000

EPS (TTM)

-0.48

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-2.70%

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

24.24

Momentum

Bearish momentum

Value

0.0190

Previous

0.0053

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025